Hiestand Roxana, Gruner Christiane
Klinik für Kardiologie, Universitätsspital Zürich, Switzerland,
Klinik für Kardiologie, Universitätsspital Zürich, Switzerland.
Ther Umsch. 2024 Apr;81(2):60-66. doi: 10.23785/TU.2024.02.006.
The new 2023 European Society of Cardiology (ESC) Guidelines for the management of cardiomyopathies addresses all cardiomyopathies in a single document for the first time. The focus is on a phenotype-oriented diagnostic approach, multimodal imaging and genetic testing to establish the most accurate diagnosis possible. Additionally, new recommendations for risk stratification for sudden cardiac death in various cardiomyopathy phenotypes are provided. MRI and genetic testing have significantly gained importance in this context. Recommendations for comprehensive clinical and genetic cascade screening in relatives of individuals with cardiomyopathies have been revised. This article presents the most important innovations of these guidelines in a practice-oriented approach.
2023年欧洲心脏病学会(ESC)心肌病管理新指南首次在一份文件中涵盖了所有心肌病。重点在于以表型为导向的诊断方法、多模态成像和基因检测,以尽可能做出最准确的诊断。此外,还提供了针对各种心肌病表型心脏性猝死风险分层的新建议。在这方面,MRI和基因检测的重要性显著增加。针对心肌病患者亲属进行全面临床和基因级联筛查的建议也已修订。本文以注重实践的方式介绍了这些指南的最重要创新之处。